Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
17. Mai 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
05. Januar 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
COCRYSTAL PHARMA, INC. ANNOUNCES CLOSING OF $2.2 MILLION REGISTERED DIRECT OFFERING
03. Februar 2020 08:05 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Feb. 03, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C
20. September 2018 08:00 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...